There Is Life After Death, At Least In Biotech

Crushing disappointment is not an uncommon occurrence in the stock market, but it is practically commonplace in the biotech sector. For every Gilead Sciences (Nasdaq: GILD) or Celgene (Nasdaq: CELG), there are many companies whose compounds fail and whose stocks wither away to mere penny prices.


That said, biotech may also be one of the resilient sectors you can find. So long as you still have a few compounds (or a few ideas) and enough cash, you will get a second chance. And if that second chance works out, you will find the market is more than willing to let bygones be bygones.

For the full column, please go to: 
http://stocks.investopedia.com/stock-analysis/2010/There-Is-Life-After-Death-At-Least-In-Biotech-GILD-CELG-NBIX-ISIS-GENZ-VVUS-NKTR0622.aspx